Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan

Tadahiro Yanagi; Kosuke Ushijima; Hidenobu Koga; Takeshi Tomomasa; Hitoshi Tajiri; Reiko Kunisaki; Takashi Isihige; Hiroyuki Yamada; Katsuhiro Arai; Atsushi Yoden; Tomoki Aomatsu; Satoru Nagata; Keiichi Uchida; Yoshikazu Ohtsuka; Toshiaki Shimizu

doi:10.5217/ir.2019.00027

Articles

Page Path: HOME > Intest Res > Volume 17(4); 2019 > Article

Original Article Inflammatory bowel diseases Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan: Tadahiro Yanagi^1,2,, Kosuke Ushijima^1,2, Hidenobu Koga³, Takeshi Tomomasa^2,4, Hitoshi Tajiri^2,5, Reiko Kunisaki^2,6, Takashi Isihige^2,7, Hiroyuki Yamada^2,8, Katsuhiro Arai^2,9, Atsushi Yoden^2,10, Tomoki Aomatsu^2,10, Satoru Nagata^2,11, Keiichi Uchida^2,12, Yoshikazu Ohtsuka^2,13, Toshiaki Shimizu^2,13; Intestinal Research 2019;17(4):476-485.
DOI: https://doi.org/10.5217/ir.2019.00027
Published online: August 31, 2019

¹Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan

²Members of the Japanese Society for Pediatric Inflammatory Bowel Disease Working Group, Japan

³Clinical Research Support Office, Aso Iizuka Hospital, Iizuka, Japan

⁴PAL Children’s Clinic, Isesaki, Japan

⁵Department of Pediatrics, Osaka General Medical Center, Osaka, Japan

⁶Inflammatory Bowel Center, Yokohama City University Medical Center, Yokohama, Japan

⁷Department of Pediatrics, Gunma University Graduate School of Medicine, Maebashi, Japan

⁸Department of Pediatric Gastroenterology, Nutrition and Endocrinology, Osaka Women’s and Children’s Hospital, Osaka, Japan

⁹Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan

¹⁰Department of Pediatrics, Osaka Medical College, Osaka, Japan

¹¹Department of Pediatrics, Tokyo Women’s Medical University Hospital, Tokyo, Japan

¹²Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Japan

¹³Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

Correspondence to Tadahiro Yanagi, Department of Pediatrics and Child Health, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. Tel: +81-942-31-7565, Fax: +81-942-38-1792, E-mail: yanagi_tadahiro@med.kurume-u.ac.jp

• Received: March 29, 2019 • Revised: June 13, 2019 • Accepted: July 15, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

13,297 Views
232 Download
10 Web of Science
8 Crossref
11 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Acknowledgments
SUPPLEMENTARY MATERIAL
REFERENCES

See letter "Tacrolimus in pediatric ulcerative colitis: does it have a role?" in Volume 17 on page 441.

Abstract

Background/Aims
Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis.
Methods
We retrospectively reviewed the multicenter survey data of 67 patients with ulcerative colitis aged < 17 years treated with tacrolimus between 2000 and 2012. Patients’ characteristics, disease activity, Pediatric Ulcerative Colitis Activity Index (PUCAI) score, initial oral tacrolimus dose, short-term (2-week) and long-term (1-year) outcomes, steroid-sparing effects, and adverse events were evaluated. Clinical remission was defined as a PUCAI score < 10; treatment response was defined as a PUCAI score reduction of ≥ 20 points compared with baseline.
Results
Patients included 35 boys and 32 girls (median [interquartile range] at admission: 13 [11–15] years). Thirty-nine patients were steroid-dependent and 26 were steroidrefractory; 20 had severe colitis and 43 had moderate colitis. The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05–0.12 mg/kg/day). The short-term clinical remission rate was 47.8%, and the clinical response rate was 37.3%. The mean prednisolone dose was reduced from 19.2 mg/day at tacrolimus initiation to 5.7 mg/day at week 8 (P< 0.001). The adverse event rate was 53.7%; 6 patients required discontinuation of tacrolimus therapy.
Conclusions
Tacrolimus was a safe and effective second-line induction therapy for steroid-dependent and steroid-refractory ulcerative colitis in Japanese children.
Keywords: Immunologic factors; Biological factors; Remission induction; Colectomy

INTRODUCTION

Pediatric patients with UC generally experience more extensive and severe disease than adult patients [1,2]. The prevalence of steroid-refractory and steroid-dependent colitis is also higher among children than among patients with adult-onset disease [2]. Steroid-dependent colitis is defined as relapse of symptoms when the steroid dose is reduced after remission, recurrence of symptoms within 3 months after steroid discontinuation, or inability to discontinue steroids within 14–16 weeks [3]. Steroids should be avoided as maintenance therapy either by increasing other maintenance therapies or by adding second-line therapy [3,4]. Steroid-refractory colitis is defined as a lack of response to adequate steroid treatment within 3–10 days. Introducing second-line therapies, such as cyclosporine, tacrolimus, or biologics, is necessary to avoid or delay surgery in steroid-refractory patients [3-6].

In 2009, tacrolimus was approved as a treatment for refractory UC, in Japan. Tacrolimus is an immunomodulator with a macrolide skeleton that was discovered as a metabolite of Streptomyces tsukubaensis and has a mode of action similar to that of cyclosporine [7]. Tacrolimus combines FKBP-12 inside the cell to form a complex. This complex inhibits calcineurin, a dephosphorylating enzyme inside the helper-T cell. Calcineurin inhibition suppresses transcription of the early activation genes for cytokines such as interleukin 2, TNF-α, and interferon-c in T cells. In summary, tacrolimus is a potent inhibitor of helper-T lymphocyte activation. The immunosuppressive effect of tacrolimus is 30–100 times greater in vitro and 10–20 times greater in vivo than that of cyclosporine [7-9]. Because tacrolimus is unaffected by bile acids and mucosal injury, intestinal absorption is more consistent than for cyclosporine, even in the presence of gastrointestinal disease [8].

A placebo-controlled double-blind study of oral tacrolimus therapy assessed efficacy in adult patients with refractory UC [10]. In a systematic review of 2 randomized controlled trials, tacrolimus at high trough concentrations showed significantly greater efficacy than placebo at 2 weeks and demonstrated significant dose-dependent efficacy in patients with UC [11].

The European Crohn’s and Colitis Organisation and the European Society for Paediatric Gastroenterology Hepatology and Nutrition guidelines for pediatric patients with UC state, “Cyclosporine or tacrolimus started during an episode of acute severe colitis should be discontinued after 4 months, bridging to thiopurines.” [3,4] In these guidelines, tacrolimus is positioned as a second-line treatment for steroid-refractory severe UC. In the Japanese treatment guidelines for UC [12], tacrolimus is listed as a treatment for fulminant or refractory UC. The Japanese guidelines state that the administration dose should aim to reach an initial serum trough level of 10–15 ng/mL and should then be adjusted to obtain an ongoing trough level of 5–10 ng/mL. After induction, treatment gradually changes to maintenance therapy with azathioprine (AZA) or 6-mercaptopurine (6-MP). The aim of this study was to evaluate the effectiveness and safety of tacrolimus for UC in children, in Japan.

METHODS

1. Patients

This study was a retrospective survey involving multiple centers in Japan. Data were collected from a multicenter survey of infliximab, adalimumab, cyclosporine, and tacrolimus use in pediatric patients diagnosed with IBD between 2000 and 2012. The survey was sent to 683 facilities in Japan from December 2012 to March 2013, including 513 pediatric facilities, 91 pediatric surgery facilities, and 79 internal medicine facilities specializing in IBD. Eligible patients for this study were Japanese children under 17 years of age with UC who were treated with tacrolimus. The diagnosis of UC was established with the Porto criteria [13] or standard criteria [14] and was based on clinical assessment, radiology, endoscopy, and histology at each facility. Steroid-refractory colitis is defined as a lack of response to adequate steroid treatment within 3–10 days. Steroid-dependent colitis is defined as relapse of symptoms when the steroid dose is reduced after remission, recurrence of symptoms within 3 months after steroid discontinuation, or inability to discontinue steroids within 14–16 weeks [3]. After identifying patients’ data for inclusion based on the medical records, each facility representative completed the secondary questionnaire (Supplementary Material 1).

2. Evaluation

The primary focus of the evaluation was short- and long-term clinical outcomes. We defined a short-term effect as a response within 2 weeks of administration of tacrolimus and long-term effects as the event-free survival rate 1 year after tacrolimus administration, which was defined as rescue therapy-free and surgery-free survival at 1 year. We used the Pediatric Ulcerative Colitis Activity Index (PUCAI) score [15], which is the standard global scoring system, and which ranges from 0 to 85, to evaluate tacrolimus efficacy. Clinical remission was defined as a PUCAI score <10; scores of 10–34 indicated mild activity, 35–64 indicated moderate activity, and ≥65 indicated severe activity. Response to tacrolimus was defined as a PUCAI score decrease of ≥20 points compared with baseline. If the PUCAI score did not change or increased, tacrolimus therapy was regarded as ineffective. Relapse was defined as an exacerbation of symptoms or an increase in PUCAI score after tacrolimus administration. The PUCAI score was determined from medical record data collected in the secondary survey. We also evaluated the following parameters at the time of tacrolimus administration: patients’ characteristics, PUCAI score, initial tacrolimus dose, highest blood trough concentration within 2 weeks of beginning tacrolimus therapy, period from diagnosis to first tacrolimus administration, tacrolimus treatment period, time to relapse after tacrolimus administration, steroid-sparing effects, and use of tacrolimus as bridge therapy to maintenance strategies among patients with remission or response. Furthermore, we analyzed any parameters associated with short- and long-term outcomes.

Second, we compared patients’ demographics, short-term tacrolimus treatment effect, time to relapse or surgery, and long-term tacrolimus treatment effect among steroid-refractory patients versus steroid-dependent patients.

Adverse events were assessed in all patients during tacrolimus administration. Complications leading to hospitalization, death, or discontinuation of treatment were considered serious adverse events.

3. Statistical Analyses

All variables are expressed as mean, medians (interquartile ranges, IQR) or number (%). We compared proportions between any 2 categorical variables with Fisher exact test and compared continuous variables with the Wilcoxon rank sum test (the Mann-Whitney U-test). One-way ANOVA or Kruskal-Wallis rank test were used to compare more than 3 or more groups of continuous variables and Fisher exact test were used for categorical variables. Kaplan-Meier estimation was used for event-free time analysis, and the log-rank test was used for these comparisons. All reported P-values are two-sided; P<0.05 was considered statistically significant.

4. Ethical Considerations

The Institutional Ethics Committees at Juntendo University and at each institution approved this study. The study protocol was publicly available on each participating institution’s homepage, and patients were free to withdraw their data from the study at any time.

RESULTS

1. Patients

We identified 88 pediatric patients with UC treated with tacrolimus, after the first survey. The secondary questionnaire survey was administered to collect data for these 88 patients, and we obtained data for 75 out of 88 patients (85.2% response rate). We retrospectively reviewed the medical records of the 75 patients and excluded 8 patients for whom the initial tacrolimus dose, colitis severity at tacrolimus administration, short-term effect, and long-term effect were not described. We included data for the remaining 67 patients, in this study. Patients’ demographics at the time of the diagnosis of UC are shown in Table 1. This study included 35 boys and 32 girls with a median age at diagnosis of 11.7 years (range, 9.2–13.7 years). Four patients (6.0%) had a family history of IBD; 23 patients had severe colitis and 34 had moderate colitis, and the median PUCAI score was 65 (range, 45–70). Regarding disease extent, almost all patients (87.7%) had pancolitis. Patients’ medical history before tacrolimus administration indicated that 5-aminosalicylic acid (5-ASA) or salazosulfapyridine (66 patients, 98.5%) and steroids (66 patients, 98.5%) were used in almost all patients. AZA/6-MP (34 patients, 50.7%) and leukocyte apheresis (32 patients, 47.8%) were used in approximately half of the patients; cyclosporine was used in 7 patients (10.4%); and anti-TNF agents were used in 3 patients (4.5%).

Patients’ demographics at the time of tacrolimus administration are shown in Table 1. The median age at administration was 13 years (range, 11–15 years); 39 patients were steroid-dependent and 26 were steroid-refractory. The remaining 2 patients did not receive steroids. One patient received tacrolimus as diarrhea worsened during administration of 5-ASA. In another patient, tacrolimus was administered because of worsening anemia during treatment with 5-ASA and leukocyte apheresis. Fifty-four patients (83.1%) had pancolitis, and 11 (16.9%) had left-sided colitis. Twenty patients (29.8%) had severe colitis, 43 (64.2%) had moderate colitis, and 4 (6.0%) had mild colitis. The median PUCAI score at administration was 55 (range, 35–65). The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05–0.12 mg/kg/day), and the highest blood trough concentration within 2 weeks was 12.4 ng/mL (range, 9.2–15.2 ng/mL). The median period from diagnosis to first administration of tacrolimus was 10.0 months (range, 2–17 months); median tacrolimus treatment duration was 18.1 weeks (range, 10.0–41.4 weeks); and the median time to relapse after tacrolimus administration was 14 weeks (range, 8–26 weeks). The mean dose of prednisolone was reduced from 19.2 mg/day at tacrolimus administration onset to 5.7 mg/day at week 8. We found a significant steroid-sparing effect of tacrolimus administration (P<0.001).

2. Primary Outcomes

Regarding short-term effects, the clinical remission rate was 47.8% (32 patients), and the clinical response rate was 37.3% (25 patients). Only 10 patients (14.9%) showed no treatment effect (Figs 1, 2). Among 57 patients (85.1%) with remission or response, 29 patients (43.2%) had received AZA before tacrolimus administration. Fifteen (22.3%) were newly-bridged to AZA after tacrolimus and 14 (93.3% of 15 patients) had relapse or surgery within 1 year.

Regarding long-term effects, only 8 patients (11.9% of all patients and 14% of patients with short-term remission or response) achieved long-term remission without relapse or surgery (Figs 1, 2). Five of the 8 patients maintained remission were treated with AZA prior to tacrolimus administration. Two patients were maintained in remission with only 5-ASA. One was administered AZA after tacrolimus administration. However, 86.0% of 57 patients with short-term remission or response relapsed or need surgery within 1 year. Twenty patients (29.9%) required surgery. Medical treatment, including biologics (22 patients, 33%), re-administration of tacrolimus (10 patients, 14.9%), and prednisolone (4 patients, 6%), was added for patients who did not require surgery. The association between each parameter and short- and long-term outcomes is shown in Tables 2 and 3. In the univariate analysis, only initial dose of tacrolimus was the significant association for long-term outcomes, but the other parameters revealed no significant difference in the short- and long-term outcomes. The short-term effects between the remission group and the response group showed no significant difference in the long-term effects in Kaplan-Meier curve analysis (log-rank test, P=0.33) (Fig. 3). We did not perform the multivariate logistic regression analysis because we did not obtain enough sample size in this study.

3. Secondary Outcomes

Thirty-nine patients (58.2%) were steroid-dependent and 26 (38.8%) were steroid-refractory. Table 1 shows patients’ demographics at the time of tacrolimus administration according to their classification as steroid-dependent or steroid-refractory. Among steroid-dependent patients, the median age was 13 years (range, 11.5–14.3 years) and 19 (48.7%) were female. Among steroid-refractory patients, the median age was 13 years (range, 9.4–15.4 years) and 12 (46.2%) were female. At the time of tacrolimus administration, a significantly greater percentage of steroid-dependent patients had received 5-ASA or AZA compared with steroid-refractory patients. Pancolitis was present in 76.9% of steroid-dependent patients and in 88.5% of steroid-refractory patients; none of these patients had proctitis. A significantly higher percentage of patients in the steroid-refractory group (46%) had severe UC compared with the steroid-dependent group. The PUCAI score was also higher in the steroid-refractory group than in the steroid-dependent group (60 [50–65] vs. 40 [25–65], respectively; P=0.038). The period from diagnosis to first administration of tacrolimus was significantly shorter in the steroid-refractory group (2 months; IQR, 1–9 months) than in the steroid-dependent group (15 months; IQR, 8–33 months).

Nineteen patients (28.3%) in the steroid-dependent group and 12 (17.9%) in the steroid- refractory group achieved short-term remission. Fourteen patients (20.9%) in the steroid-dependent group and 11 (16.4%) in the steroid-refractory group achieved short-term treatment response. The difference in the rate of short-term remission and response between groups was not significant (P=0.686).

Twenty-five steroid-dependent patients (37.3%) and 21 steroid-refractory patients (31.3%) had short-term remission or response but relapsed or needed surgery within 1 year. Among patients with remission or response, patients in the steroid-dependent group relapsed 280 days (range, 56–301 days) after tacrolimus administration; patients in the steroid-refractory group relapsed 148 days (range, 56–196 days) after tacrolimus administration. The time interval to relapse or colectomy was not significantly different between groups, according to Kaplan-Meier curve analysis (log-rank test, P=0.52) (Fig. 4).

4. Safety

Adverse events were identified in 36 out of 67 patients (53.7%). Asymptomatic hypomagnesemia occurred in 9 patients (13.4%) and tremor in 7 patients (10.4%) (Table 4). Six patients (9.0%) required discontinuation of tacrolimus therapy because of adverse events: 2 (3.0%) had renal impairment, 2 (3.0%) had myelosuppression, 1 (1.5%) developed intestinal infection, and 1 (1.5%) experienced vomiting. The highest trough concentrations for cases with discontinuation were 6.2 to 13.6 ng/mL, all less than 15 ng/mL. All symptoms improved after tacrolimus discontinuation or with appropriate treatment.

DISCUSSION

We retrospectively investigated the effectiveness and safety of tacrolimus as second-line treatment for pediatric UC using a multicenter survey. In our study, the rate of remission or response at 2 weeks was 85.1%, and the clinical remission rate was 47.8% within 2 weeks. Pediatric UC is characterized by more extensive and rapid progression than adult-onset UC, and pediatric patients are more likely to have acute severe exacerbations and lack of response to steroid therapy [1-4,16]. The steroid failure rate was reported as 34%; therefore, especially in severe cases, second-line therapy should be introduced at an appropriate time to avoid or delay colectomy [4-6]. Turner et al. [17,18] proposed determining the timing of second-line therapy based on PUCAI scores.

Second-line therapies for induction of remission in steroid-refractory and steroid-dependent pediatric patients with UC include cyclosporine, anti-TNF-α agents, and tacrolimus [3-6,16,17]. The reported short-term response rate to cyclosporine among pediatric patients is 81% (range, 76%–86%) [6], and the reported response rate to infliximab is 75% (range, 67%–83%) [6]. A double-blind study of adult patients showed a tacrolimus efficacy of 68.4% [10]; however, reports of tacrolimus use for pediatric patients with UC are limited. The effects of tacrolimus for pediatric UC were first reported in 1996 [19], and in 2000, a multicenter study reported the effects of tacrolimus in 10 pediatric patients with UC [20]. Five retrospective studies of tacrolimus administration in children with UC [5,19-22] reported a pooled short-term response rate of 79% (range, 68%–87%) among patients with steroid-refractory UC [5]. Similar to previous reports, we found that tacrolimus was an effective second-line induction therapy in steroid-refractory and steroid-dependent pediatric patients with UC. In our study, the rate of remission or response 2 weeks after beginning tacrolimus was 85.1%, and the clinical remission rate was 47.8% within 2 weeks. Ogata et al. [10] demonstrated that their high-trough group (10–15 ng/mL) had a higher remission rate than the low-trough and placebo groups. However, in our study, we found no significant difference in short-term effects based on the initial tacrolimus dose or trough level, although many patients had no documented trough level in the target zone. The fact that the initial dosage and dose regulation varied widely by facility is suspected to have strongly influenced our results when evaluating the short-term effects of tacrolimus therapy. Although previous studies cited the steroid-sparing effect of tacrolimus administration, no clear numerical value was reported in previous pediatric studies. Similar to a study of adults with UC [10], tacrolimus use in this study resulted in a significant steroid-sparing effect, with a reduction in prednisolone dose from 19.2 mg/day initially to 5.7 mg/day.

The reported pooled rate of colectomy-free status 1–2 years after tacrolimus administration in pediatric steroid-refractory UC is 43% (range, 32%–54%) [5]. A meta-analysis of observational studies in adults reported a higher colectomy-free rate of 69% among patients with moderate-to-severe UC [11]. However, only 14% of our patients with an initial response to tacrolimus maintained remission without relapse. Even though 1 patient was changed to AZA therapy, only 8 patients remained in remission 1 year after tacrolimus administration. After an initial response to tacrolimus, 82.5% of our patients experienced relapse, and many of these patients underwent third-line therapy with biologics, readministration of tacrolimus, or steroids, and were able to avoid surgery. The European Crohn’s and Colitis Organisation guidelines address bridging to AZA/6-MP for maintenance therapy [3,4,6]. Watson et al. [22] reported that maintenance to a remission of 50% has been obtained in the long-term by bridging to AZA/6-MP (30%) or infliximab (20%) after administration of tacrolimus to steroid-refractory pediatric patients. However, in our study, the large number of steroid-dependent patients and the fact that 50% of the cases had been administered AZA before the introduction of tacrolimus may have led to a reduction in long-term effects. On the other hand, 15 patients with remission or response in the short-term effect were newly-bridged to azathioprine after tacrolimus, but only 1 patient could achieve remission after 1 year without rescue therapy. Thiopurine preparations alone may be insufficient to maintain long-term remission; however, it is possible that tacrolimus will be a useful bridge therapy for vedolizumab in future [4,23].

In univariate analysis, although the initial dose of tacrolimus was associated with the long-term effect, the long-term effect due to the difference of short-term outcomes was not significantly different, and no factor related to the short- and long-term outcomes could be found. Ziring et al. [21] reported long-term outcomes in steroid-dependent and steroid-refractory patients with pediatric UC. All 9 patients with steroid-refractory UC in that study underwent colectomy within 1 year, whereas 7 out of 9 patients with steroid-dependent UC maintained remission at 1 year. In our study, the event-free survival rate was not significantly different between steroid-dependent and steroid-refractory groups. In steroid-refractory as well as steroid-dependent patients, we should carefully observe the clinical course after response to tacrolimus, considering the possibility of surgery.

Adverse events occurred in 53.7% of all patients in our study. Ogata et al. [10] reported that 81.3% of patients who received tacrolimus had adverse events; however, many of these were mild symptoms, and the authors found no significant difference in the incidence of severe adverse events between the tacrolimus group and placebo group. In contrast, Komaki et al. [11] suggested that adverse events were more common with tacrolimus than with other treatments, which is 1 reason that administration of tacrolimus is limited to facilities with relatively more patient experience. In studies of pediatric patients [5,19-22], hypertension, tremor, hyperglycemia, headache, infection, nephrotoxicity, and seizure have been reported with tacrolimus use, but there have been no reports of serious adverse events. Renal impairment has been reported often, and the incidence of nephrotoxicity is increasing because the duration of tacrolimus administration has increased [24]. Four of our patients (6%) experienced renal impairment, and tacrolimus was discontinued in 2 of these patients; both improved after discontinuing short-term tacrolimus.

One limitation of our study is its retrospective design. Additionally, patients’ backgrounds in both the acute severe ulcerative group and in many steroid-dependent patients, initial tacrolimus dose, dose adjustment differences among institutions, and variations in trough levels appear to have influenced the short-term effects following tacrolimus therapy. In addition, several different drugs were being coadministered at the beginning of tacrolimus administration, which is a confounding factor. Regarding the long-term event-free survival rate, several treatment interventions were performed during relapse; therefore, we could not evaluate these rates accurately.

This retrospective study demonstrated that tacrolimus may be useful to induce short-term treatment response and may delay the need for colectomy in pediatric patients with steroid-dependent and steroid-refractory UC. No serious adverse events were seen in this study; tacrolimus was safely administered short-term, in our patients.

Despite the high rate of remission induction, only 14% of our patients maintained remission, and approximately 30% eventually required colectomy during long-term follow-up. Even if tacrolimus is effective, careful follow-up observation is necessary given the possible need for surgery. It is possible that bridging to AZA alone may not maintain long-term remission. Future studies are needed to determine how to maintain the effects of tacrolimus long-term.

NOTES

FINANCIAL SUPPORT

This work was supported in part by Health and Labor Sciences Research Grants for research on intractable disease from the Ministry of Health, Labour, and Welfare of Japan.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTION

Conceptualization: Yanagi T, Ushijima K. Methodology: Yanagi T, Tomomasa T, Tajiri H, Kunisaki R, Isihige T, Yamada H, Arai K, Yoden A, Aomatsu T, Nagata S, Uchida K, Ohtsuka Y, Shimizu T. Formal analysis: Yanagi T, Koga H. Writing - original draft: Yanagi T. Writing - review and editing: Yanagi T. Approval of final manuscript: all authors.

Acknowledgments

The authors thank the participating members of the Ministry of Health, Labour and Welfare of Japan’s Inflammatory Bowel Diseases Study Group, especially the Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University (Mamoru Watanabe); Department of Internal Medicine, Sakura Medical Center, Toho University (Yasuo Suzuki); Department of Internal Medicine, National Defense Medical College (Soichiro Miura and Ryota Hokari); and the Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University (Toshifumi Hibi) for their contributions to this work.

SUPPLEMENTARY MATERIAL

Supplementary Material 1. Supplement tacrolimus treatment questionnaire for pediatric UC.

ir-2019-00027-suppl.pdf

Fig. 1.

Patient flow of short- and long-term effects in this study.

Fig. 2.

Short- and long-term effects of tacrolimus therapy. Short-term effects, defined as remission or response within 2 weeks of tacrolimus therapy, were achieved in 85.1% of patients (remission: 47.8%; response: 37.3%). As a long-term effect, the event-free survival rate was 11.9% (14% of those who achieved short-term remission or response).

Fig. 3.

Event-free survival rate between remission and response groups classified according to short-term effect. We found no significant difference between the 2 groups (remission and response) for the event-free survival rate 1 year after tacrolimus administration, based on Kaplan-Meier analysis (log-rank test, P=0.33).

Fig. 4.

Event-free survival rate in the steroid-dependent and steroid-refractory groups. We found no significant difference between steroid-dependent and steroid-refractory groups for the event-free survival rate 1 year after tacrolimus administration, based on Kaplan-Meier analysis (log-rank test, P=0.52).

Table 1.

Patient’s Demographics (n=67)

Variable	At diagnosis	Before administration	At administration
Variable	At diagnosis	Before administration	All patients (n = 67)	Steroid-dependent (n = 39)	Steroid-refractory (n = 26)	P-value^a
Sex						1.000
Male	35 (52.2)			20 (51.3)	14 (53.8)
Female	32 (47.8)			19 (48.7)	12 (46.2)
Age (yr)	11.7 (9.2–13.7)		13.0 (11.0–15.0)	13.0 (11.5–14.3)	13.0 (9.4–15.4)	0.940
Family history	4 (6.0)
Medical history
5-ASA		66 (98.5)	56 (83.6)	36 (92.3)	18 (69.2)	0.021
Steroid		66 (98.5)	49 (73.1)	23 (59.0)	26 (100.0)	< 0.001
AZA/6-MP		34 (50.7)	26 (38.8)	20 (51.3)	6 (23.1)	0.038
Leukocyte apheresis		32 (47.8)	13 (19.4)	6 (15.4)	6 (23.1)	0.520
Cyclosporine		7 (10.4)	1 (1.5)	0	1 (3.8)	0.400
Anti-TNF agents		3 (4.5)	0	0	0
Extent of disease^b						0.074
Proctitis	3 (4.6)		0	0	0
Left-sided	5 (7.7)		11 (16.9)	9 (23.1)	1 (3.8)
Pancolitis	57 (87.7)		54 (83.1)	30 (76.9)	23 (88.5)
Severity^c						0.020
Mild	3 (5.0)		4 (6.0)	4 (10.3)	0
Moderate	34 (56.7)		43 (64.2)	28 (71.8)	14 (53.8)
Severe	23 (38.3)		20 (29.8)	7 (17.9)	12 (46.2)
PUCAI	65 (45.0–70.0)		55 (35.0–65.0)	40 (25.0–65.0)	60 (50.0–65.0)	0.038
Period from diagnosis to first administration of tacrolimus (mon)			10 (2–17)	15 (8–33)	2 (1–9)	< 0.001
Tacrolimus
Initial dose (mg/kg/day)			0.09 (0.05–0.12)	0.08 (0.05–0.10)	0.09 (0.05–0.12)	0.460
Highest blood trough concentration (ng/mL)			12.4 (9.2–15.2)	11.9 (7.6–14.3)	12.8 (10.3–16.2)	0.290

Values are presented as number (%) or median (interquartile range).

^a Fisher exact test for comparisons between steroid-dependent and steroid-refractory groups.

^b Includes 65 patients; 2 patients had no data. There were 24 steroid-refractory patients, and 2 patients had no data.

^c Includes 60 cases at diagnosis; 7 patients had no data.

5-ASA, 5-aminosalicylic acid; AZA, azathioprine; 6-MP, 6-mercaptopurine; PUCAI, Pediatric Ulcerative Colitis Activity Index.

Table 2.

Association between Each Parameters and Short-term Outcomes

Variable	Short-term effect			P-value^a
Variable	Remission (n = 32)	Response (n = 25)	No effect (n = 10)	P-value^a
Male sex	15 (22.3)	12 (17.9)	8 (11.9)	0.169
Age (yr) at tacrolimus administration	12.9 (11.7–15.2)	11.1 (8.0–14.5)	13.1 (11.8–15.3)	0.460
Period from diagnosis to first tacrolimus administration (mon)	14.8 (2.0–28.5)	14.2 (2.0–17.0)	11.3 (3.0–12.0)	0.910
Severity				0.830
Severe	9 (13.4)	9 (13.4)	2 (3.0)
Moderate	21 (31.3)	15 (22.3)	7 (10.4)
Mild	2 (3.0)	1 (1.5)	1 (1.5)
PUCAI^b	45.5 (25.0–65.0)	57.4 (50.0–65.0)	48.3 (40.0–60.0)	0.178
Reason for tacrolimus administration				0.630
Steroid-dependent	19 (28.3)	14 (20.9)	6 (9.0)
Steroid-refractory	12 (17.9)	11 (16.4)	3 (4.5)
Others	1 (1.5)	0	1 (1.5)
Initial dose (mg/kg/day)	0.09 (0.05–0.12)	0.09 (0.06–0.12)	0.08 (0.05–0.10)	0.870
Highest blood trough concentration (ng/mL)	12.2 (9.3–13.8)	11.6 (9.2–15.7)	12.4 (10.0–15.6)	0.680

Values are presented as number (%) or median (interquartile range).

^a Fisher exact test or Kruskal-Wallis test.

^b Includes 60 cases at diagnosis; 7 patients had no data.

PUCAI, Pediatric Ulcerative Colitis Activity Index.

Table 3.

Association between Each Parameters and Long-term Outcomes

Variable	Long-term effect		P-value^a
Variable	Remission (n=8)	Relapse or surgery (n=49)^b	P-value^a
Male sex	5 (8.8)	22 (38.6)	0.450
Age (yr) at tacrolimus administration	12.2 (11.5–14.8)	12.1 (10.0–14.8)	0.890
Period from diagnosis to first tacrolimus administration (mon)	12.4 (2.0–23.5)	14.9 (2.0–17.0)	0.850
Severity			0.240
Severe	1 (1.8)	17 (29.8)
Moderate	6 (10.5)	30 (52.6)
Mild	1 (1.8)	2 (3.5)
PUCAI^c	37.1 (20.0–60.0)	53.1 (40.0–65.0)	0.085
Reason for tacrolimus administration			0.520
Steroid-dependent	6 (10.5)	27 (47.3)
Steroid-refractory	2 (3.5)	21 (36.8)
Others	0	1 (1.8)
Initial dose (mg/kg/day)	0.07 (0.45–0.65)	0.10 (0.06–0.12)	0.027
Highest blood trough concentration (ng/mL)	14.1 (10.3–17.5)	11.6 (8.9–14.3)	0.570

Values are presented as number (%) or median (interquartile range).

^a Fisher exact test or Kruskal-Wallis test.

^b Includes 59 patients; 10 cases had unclear timing data of relapse or surgery.

^c Includes 51 cases at diagnosis; 6 patients had no data.

PUCAI, Pediatric Ulcerative Colitis Activity Index.

Table 4.

Adverse Events (n=67)

Adverse event	No. (%)	Discontinuation of tacrolimus, no. (%)
Hypomagnesemia	9 (13.4)	-
Tremor	7 (10.4)	-
Infection	4 (6.0)	1 (1.5)
Renal impairment	4 (6.0)	2 (3.0)
Myelosuppression	4 (6.0)	2 (3.0)
Hyperglycemia	3 (4.5)	-
Headache	2 (3.0)	-
Hyperkalemia	2 (3.0)	-
Vomiting	1 (1.5)	1 (3.0)
Pancreatitis	1 (1.5)	-
Hyperuricemia	1 (1.5)	-
Total no. of patients experiencing adverse events	36 (53.7)	6 (9.0)

Two patients had more than 1 adverse event.

REFERENCES

1. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114–1122.Article PubMed
2. Ishige T, Tomomasa T, Takebayashi T, et al. Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in Japan. J Gastroenterol 2010;45:911–917.Article PubMed PDF
3. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55:340–361.Article PubMed
4. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292–310.Article PubMed
5. Navas-López VM, Blasco Alonso J, Serrano Nieto MJ, Girón Fernández-Crehuet F, Argos Rodriguez MD, Sierra Salinas C. Oral tacrolimus for pediatric steroid-resistant ulcerative colitis. J Crohns Colitis 2014;8:64–69.Article PubMed PDF
6. Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011;17:440–449.Article PubMed
7. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987;40:1256–1265.Article PubMed
8. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995;52:1521–1535.Article PubMed PDF
9. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249–1255.Article PubMed
10. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255–1262.Article PubMed PMC
11. Komaki Y, Komaki F, Ido A, Sakuraba A. Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis. J Crohns Colitis 2016;10:484–494.Article PubMed PDF
12. Matsuoka K, Hibi T. Treatment guidelines in inflammatory bowel disease: the Japanese perspectives. Dig Dis 2013;31:363–367.Article PubMed
13. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1–7.Article PubMed
14. Marion JF, Rubin PH, Present DH. Differential diagnosis of chronic ulcerative colitis and Crohn’s disease. In: Kirsner JB. eds. Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders, 2000:315–325.
15. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a Pediatric Ulcerative Colitis Activity Index: a prospective multicenter study. Gastroenterology 2007;133:423–432.Article PubMed
16. Romano C, Syed S, Valenti S, Kugathasan S. Management of acute severe colitis in children with ulcerative colitis in the biologics era. Pediatrics 2016;137:e20151184.Article PubMed
17. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008;57:331–338.Article PubMed
18. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282–2291.Article PubMed
19. Bousvaros A, Wang A, Leichtner AM. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996;23:329–333.Article PubMed
20. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000;137:794–799.Article PubMed
21. Ziring DA, Wu SS, Mow WS, Martín MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007;45:306–311.Article PubMed
22. Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 2011;17:22–29.Article PubMed
23. Hamel B, Wu M, Hamel EO, Bass DM, Park KT. Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis. BMJ Open Gastroenterol 2018;5:e000195.Article PubMed PMC
24. Hosoi K, Arai K, Matsuoka K, et al. Prolonged tacrolimus for pediatric gastrointestinal disorder: double-edged sword? Pediatr Int 2017;59:588–592.Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis
Perseus V. Patel, Amy Zhang, Balu Bhasuran, Vignesh G. Ravindranath, Melvin B. Heyman, Sofia G. Verstraete, Atul J. Butte, Michael J. Rosen, Vivek A. Rudrapatna
Journal of Pediatric Gastroenterology and Nutrition.2024; 78(5): 1126. CrossRef
Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef
Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study
Ryusuke Nambu, Katsuhiro Arai, Takahiro Kudo, Takatsugu Murakoshi, Reiko Kunisaki, Tatsuki Mizuochi, Sawako Kato, Hideki Kumagai, Mikihiro Inoue, Takashi Ishige, Takeshi Saito, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Naomi Iwata, Shigeo N
Journal of Gastroenterology.2023; 58(5): 472. CrossRef
Oral Tacrolimus in Steroid Refractory and Dependent Pediatric Ulcerative Colitis—A Systematic Review and Meta-Analysis
Rishi Bolia, Akhil Goel, Pooja Semwal, Anshu Srivastava
Journal of Pediatric Gastroenterology & Nutrition.2023; 77(2): 228. CrossRef
Tacrolimus as an alternative treatment for patients with juvenile idiopathic arthritis
Susumu Yamazaki, Masaki Shimizu, Yuko Akutsu, Asami Shimbo, Masaaki Mori
Modern Rheumatology.2022; 32(4): 783. CrossRef
3D printed tacrolimus suppositories for the treatment of ulcerative colitis
Iria Seoane-Viaño, Jun Jie Ong, Asteria Luzardo-Álvarez, Miguel González-Barcia, Abdul W. Basit, Francisco J. Otero-Espinar, Alvaro Goyanes
Asian Journal of Pharmaceutical Sciences.2021; 16(1): 110. CrossRef
Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
Intestinal Research.2021; 19(4): 357. CrossRef
Tacrolimus in pediatric ulcerative colitis: does it have a role?
Seung Kim
Intestinal Research.2019; 17(4): 441. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan

Intest Res. 2019;17(4):476-485. Published online August 31, 2019

DOI: https://doi.org/10.5217/ir.2019.00027

XML Download

Figure

Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan

Fig. 1. Patient flow of short- and long-term effects in this study.

Fig. 2. Short- and long-term effects of tacrolimus therapy. Short-term effects, defined as remission or response within 2 weeks of tacrolimus therapy, were achieved in 85.1% of patients (remission: 47.8%; response: 37.3%). As a long-term effect, the event-free survival rate was 11.9% (14% of those who achieved short-term remission or response).

Fig. 3. Event-free survival rate between remission and response groups classified according to short-term effect. We found no significant difference between the 2 groups (remission and response) for the event-free survival rate 1 year after tacrolimus administration, based on Kaplan-Meier analysis (log-rank test, P=0.33).

Fig. 4. Event-free survival rate in the steroid-dependent and steroid-refractory groups. We found no significant difference between steroid-dependent and steroid-refractory groups for the event-free survival rate 1 year after tacrolimus administration, based on Kaplan-Meier analysis (log-rank test, P=0.52).

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan

Variable	At diagnosis	Before administration	At administration
Variable	At diagnosis	Before administration	All patients (n = 67)	Steroid-dependent (n = 39)	Steroid-refractory (n = 26)	P-value^a
Sex						1.000
Male	35 (52.2)			20 (51.3)	14 (53.8)
Female	32 (47.8)			19 (48.7)	12 (46.2)
Age (yr)	11.7 (9.2–13.7)		13.0 (11.0–15.0)	13.0 (11.5–14.3)	13.0 (9.4–15.4)	0.940
Family history	4 (6.0)
Medical history
5-ASA		66 (98.5)	56 (83.6)	36 (92.3)	18 (69.2)	0.021
Steroid		66 (98.5)	49 (73.1)	23 (59.0)	26 (100.0)	< 0.001
AZA/6-MP		34 (50.7)	26 (38.8)	20 (51.3)	6 (23.1)	0.038
Leukocyte apheresis		32 (47.8)	13 (19.4)	6 (15.4)	6 (23.1)	0.520
Cyclosporine		7 (10.4)	1 (1.5)	0	1 (3.8)	0.400
Anti-TNF agents		3 (4.5)	0	0	0
Extent of disease^b						0.074
Proctitis	3 (4.6)		0	0	0
Left-sided	5 (7.7)		11 (16.9)	9 (23.1)	1 (3.8)
Pancolitis	57 (87.7)		54 (83.1)	30 (76.9)	23 (88.5)
Severity^c						0.020
Mild	3 (5.0)		4 (6.0)	4 (10.3)	0
Moderate	34 (56.7)		43 (64.2)	28 (71.8)	14 (53.8)
Severe	23 (38.3)		20 (29.8)	7 (17.9)	12 (46.2)
PUCAI	65 (45.0–70.0)		55 (35.0–65.0)	40 (25.0–65.0)	60 (50.0–65.0)	0.038
Period from diagnosis to first administration of tacrolimus (mon)			10 (2–17)	15 (8–33)	2 (1–9)	< 0.001
Tacrolimus
Initial dose (mg/kg/day)			0.09 (0.05–0.12)	0.08 (0.05–0.10)	0.09 (0.05–0.12)	0.460
Highest blood trough concentration (ng/mL)			12.4 (9.2–15.2)	11.9 (7.6–14.3)	12.8 (10.3–16.2)	0.290

Variable	Short-term effect			P-value^a
Variable	Remission (n = 32)	Response (n = 25)	No effect (n = 10)	P-value^a
Male sex	15 (22.3)	12 (17.9)	8 (11.9)	0.169
Age (yr) at tacrolimus administration	12.9 (11.7–15.2)	11.1 (8.0–14.5)	13.1 (11.8–15.3)	0.460
Period from diagnosis to first tacrolimus administration (mon)	14.8 (2.0–28.5)	14.2 (2.0–17.0)	11.3 (3.0–12.0)	0.910
Severity				0.830
Severe	9 (13.4)	9 (13.4)	2 (3.0)
Moderate	21 (31.3)	15 (22.3)	7 (10.4)
Mild	2 (3.0)	1 (1.5)	1 (1.5)
PUCAI^b	45.5 (25.0–65.0)	57.4 (50.0–65.0)	48.3 (40.0–60.0)	0.178
Reason for tacrolimus administration				0.630
Steroid-dependent	19 (28.3)	14 (20.9)	6 (9.0)
Steroid-refractory	12 (17.9)	11 (16.4)	3 (4.5)
Others	1 (1.5)	0	1 (1.5)
Initial dose (mg/kg/day)	0.09 (0.05–0.12)	0.09 (0.06–0.12)	0.08 (0.05–0.10)	0.870
Highest blood trough concentration (ng/mL)	12.2 (9.3–13.8)	11.6 (9.2–15.7)	12.4 (10.0–15.6)	0.680

Variable	Long-term effect		P-value^a
Variable	Remission (n=8)	Relapse or surgery (n=49)^b	P-value^a
Male sex	5 (8.8)	22 (38.6)	0.450
Age (yr) at tacrolimus administration	12.2 (11.5–14.8)	12.1 (10.0–14.8)	0.890
Period from diagnosis to first tacrolimus administration (mon)	12.4 (2.0–23.5)	14.9 (2.0–17.0)	0.850
Severity			0.240
Severe	1 (1.8)	17 (29.8)
Moderate	6 (10.5)	30 (52.6)
Mild	1 (1.8)	2 (3.5)
PUCAI^c	37.1 (20.0–60.0)	53.1 (40.0–65.0)	0.085
Reason for tacrolimus administration			0.520
Steroid-dependent	6 (10.5)	27 (47.3)
Steroid-refractory	2 (3.5)	21 (36.8)
Others	0	1 (1.8)
Initial dose (mg/kg/day)	0.07 (0.45–0.65)	0.10 (0.06–0.12)	0.027
Highest blood trough concentration (ng/mL)	14.1 (10.3–17.5)	11.6 (8.9–14.3)	0.570

Adverse event	No. (%)	Discontinuation of tacrolimus, no. (%)
Hypomagnesemia	9 (13.4)	-
Tremor	7 (10.4)	-
Infection	4 (6.0)	1 (1.5)
Renal impairment	4 (6.0)	2 (3.0)
Myelosuppression	4 (6.0)	2 (3.0)
Hyperglycemia	3 (4.5)	-
Headache	2 (3.0)	-
Hyperkalemia	2 (3.0)	-
Vomiting	1 (1.5)	1 (3.0)
Pancreatitis	1 (1.5)	-
Hyperuricemia	1 (1.5)	-
Total no. of patients experiencing adverse events	36 (53.7)	6 (9.0)

Table 1. Patient’s Demographics (n=67)

Values are presented as number (%) or median (interquartile range).

Fisher exact test for comparisons between steroid-dependent and steroid-refractory groups.

Includes 65 patients; 2 patients had no data. There were 24 steroid-refractory patients, and 2 patients had no data.

Includes 60 cases at diagnosis; 7 patients had no data.

5-ASA, 5-aminosalicylic acid; AZA, azathioprine; 6-MP, 6-mercaptopurine; PUCAI, Pediatric Ulcerative Colitis Activity Index.

Table 2. Association between Each Parameters and Short-term Outcomes

Values are presented as number (%) or median (interquartile range).

Fisher exact test or Kruskal-Wallis test.

Includes 60 cases at diagnosis; 7 patients had no data.

PUCAI, Pediatric Ulcerative Colitis Activity Index.

Table 3. Association between Each Parameters and Long-term Outcomes

Values are presented as number (%) or median (interquartile range).

Fisher exact test or Kruskal-Wallis test.

Includes 59 patients; 10 cases had unclear timing data of relapse or surgery.

Includes 51 cases at diagnosis; 6 patients had no data.

PUCAI, Pediatric Ulcerative Colitis Activity Index.

Table 4. Adverse Events (n=67)

Two patients had more than 1 adverse event.